In our cohort study, genetic alterations in or directly influencing the WNT pathway, directly influencing chromatin remodelling, in the PI3K pathway, and upstream in EGFR or other receptor tyrosine kinases seem to predict for non-response as these mutations probably are considered driver mutations in BRAFV600E mutant CRC. This evidence concerns the gene EGFR and colorectal carcinoma.